Is Immunovant Stock a Good Investment?
Immunovant Investment Advice | IMVT |
- Examine Immunovant's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Immunovant's leadership team and their track record. Good management can help Immunovant navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Immunovant's business and its evolving consumer preferences.
- Compare Immunovant's performance and market position to its competitors. Analyze how Immunovant is positioned in terms of product offerings, innovation, and market share.
- Check if Immunovant pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Immunovant's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Immunovant stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Immunovant is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Average | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Immunovant Stock
Researching Immunovant's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 58.0% of the company shares are held by company insiders. The company recorded a loss per share of 2.62. Immunovant had not issued any dividends in recent years.
To determine if Immunovant is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Immunovant's research are outlined below:
| Immunovant generated a negative expected return over the last 90 days | |
| Immunovant has high historical volatility and very poor performance | |
| Immunovant has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (259.34 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Immunovant currently holds about 427.2 M in cash with (214.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.66. | |
| Roughly 58.0% of the company shares are held by company insiders | |
| Latest headline from benzinga.com: Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data |
Immunovant uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Immunovant. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Immunovant's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 2nd of February 2024 Upcoming Quarterly Report | View | |
| 27th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of May 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of March 2023 Last Financial Announcement | View |
Earnings surprises can significantly impact Immunovant's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Immunovant's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2020-02-14 | 2019-12-31 | -0.25 | -0.28 | -0.03 | 12 | ||
2021-06-01 | 2021-03-31 | -0.33 | -0.29 | 0.04 | 12 | ||
2022-08-05 | 2022-06-30 | -0.4 | -0.35 | 0.05 | 12 | ||
2020-08-12 | 2020-06-30 | -0.33 | -0.38 | -0.05 | 15 | ||
2021-02-16 | 2020-12-31 | -0.26 | -0.32 | -0.06 | 23 | ||
2024-08-06 | 2024-06-30 | -0.53 | -0.6 | -0.07 | 13 | ||
2024-02-12 | 2023-12-31 | -0.43 | -0.36 | 0.07 | 16 | ||
2021-11-05 | 2021-09-30 | -0.28 | -0.35 | -0.07 | 25 |
Know Immunovant's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Immunovant is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Immunovant backward and forwards among themselves. Immunovant's institutional investor refers to the entity that pools money to purchase Immunovant's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Two Seas Capital Lp | 2024-12-31 | 1.5 M | Viking Global Investors Lp | 2024-12-31 | 1.4 M | Pictet Asset Manangement Sa | 2024-12-31 | 1.2 M | Jpmorgan Chase & Co | 2024-12-31 | 1.2 M | Hood River Capital Management Llc | 2024-12-31 | 1.1 M | Stempoint Capital Lp | 2024-12-31 | 1.1 M | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 1 M | Franklin Resources Inc | 2024-12-31 | 984.1 K | T. Rowe Price Associates, Inc. | 2024-12-31 | 916.2 K | Fmr Inc | 2024-12-31 | 13.1 M | Vanguard Group Inc | 2024-12-31 | 6.7 M |
Immunovant's market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.21 B.Market Cap |
|
Immunovant's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.35) | (0.37) | |
| Return On Capital Employed | (0.53) | (0.50) | |
| Return On Assets | (0.35) | (0.37) | |
| Return On Equity | (0.48) | (0.46) |
Determining Immunovant's profitability involves analyzing its financial statements and using various financial metrics to determine if Immunovant is a good buy. For example, gross profit margin measures Immunovant's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Immunovant's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Immunovant's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Immunovant. Check Immunovant's Beneish M Score to see the likelihood of Immunovant's management manipulating its earnings.
Evaluate Immunovant's management efficiency
Immunovant has return on total asset (ROA) of (0.4473) % which means that it has lost $0.4473 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7417) %, meaning that it created substantial loss on money invested by shareholders. Immunovant's management efficiency ratios could be used to measure how well Immunovant manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.37 in 2025. Return On Capital Employed is likely to gain to -0.5 in 2025. Total Current Liabilities is likely to gain to about 58.7 M in 2025, whereas Liabilities And Stockholders Equity is likely to drop slightly above 386.8 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.03 | 2.08 | |
| Tangible Book Value Per Share | 4.03 | 2.08 | |
| Enterprise Value Over EBITDA | (15.89) | (16.68) | |
| Price Book Value Ratio | 8.13 | 7.72 | |
| Enterprise Value Multiple | (15.89) | (16.68) | |
| Price Fair Value | 8.13 | 7.72 | |
| Enterprise Value | 1.4 B | 1.4 B |
The leadership approach at Immunovant's fosters a culture of excellence and accountability. Our analysis examines how this culture influences financial outcomes and stock valuation.
Beta 0.676 |
Basic technical analysis of Immunovant Stock
As of the 20th of March, Immunovant retains the Market Risk Adjusted Performance of (0.66), risk adjusted performance of (0.15), and Standard Deviation of 3.35. Immunovant technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.Immunovant's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Immunovant insiders, such as employees or executives, is commonly permitted as long as it does not rely on Immunovant's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Immunovant insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Immunovant's Outstanding Corporate Bonds
Immunovant issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Immunovant uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Immunovant bonds can be classified according to their maturity, which is the date when Immunovant has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| US45258LAA52 Corp BondUS45258LAA52 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Understand Immunovant's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Immunovant's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.15) | |||
| Market Risk Adjusted Performance | (0.66) | |||
| Mean Deviation | 2.53 | |||
| Coefficient Of Variation | (570.42) | |||
| Standard Deviation | 3.35 | |||
| Variance | 11.19 | |||
| Information Ratio | (0.16) | |||
| Jensen Alpha | (0.53) | |||
| Total Risk Alpha | (0.31) | |||
| Treynor Ratio | (0.67) | |||
| Maximum Drawdown | 18.14 | |||
| Value At Risk | (5.95) | |||
| Potential Upside | 5.03 | |||
| Skewness | (0.29) | |||
| Kurtosis | 1.02 |
| Risk Adjusted Performance | (0.15) | |||
| Market Risk Adjusted Performance | (0.66) | |||
| Mean Deviation | 2.53 | |||
| Coefficient Of Variation | (570.42) | |||
| Standard Deviation | 3.35 | |||
| Variance | 11.19 | |||
| Information Ratio | (0.16) | |||
| Jensen Alpha | (0.53) | |||
| Total Risk Alpha | (0.31) | |||
| Treynor Ratio | (0.67) | |||
| Maximum Drawdown | 18.14 | |||
| Value At Risk | (5.95) | |||
| Potential Upside | 5.03 | |||
| Skewness | (0.29) | |||
| Kurtosis | 1.02 |
Consider Immunovant's intraday indicators
Immunovant intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Immunovant stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Immunovant Corporate Filings
8K | 19th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 11th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 7th of March 2025 Other Reports | ViewVerify | |
| 21st of January 2025 Other Reports | ViewVerify |
Immunovant Stock media impact
Far too much social signal, news, headlines, and media speculation about Immunovant that are available to investors today. That information is available publicly through Immunovant media outlets and privately through word of mouth or via Immunovant internal channels. However, regardless of the origin, that massive amount of Immunovant data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Immunovant news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Immunovant relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Immunovant's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Immunovant alpha.
Immunovant Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Immunovant can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Immunovant Historical Investor Sentiment
Investor biases related to Immunovant's public news can be used to forecast risks associated with an investment in Immunovant. The trend in average sentiment can be used to explain how an investor holding Immunovant can time the market purely based on public headlines and social activities around Immunovant. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Immunovant's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Immunovant and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Immunovant news discussions. The higher the estimate score, the more favorable the investor's outlook on Immunovant.
Immunovant Corporate Management
| Jay Stout | Chief Officer | Profile | |
| Mark Levine | Chief Secretary | Profile | |
| Lauren MBA | Vice Marketing | Profile | |
| JD Esq | Chief Secretary | Profile | |
| Eva MBA | Chief Officer | Profile | |
| Julie Kirschling | Senior Management | Profile | |
| Christine Blodgett | Senior Resources | Profile |
Additional Tools for Immunovant Stock Analysis
When running Immunovant's price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.